ClearPoint Neuro, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
ClearPoint Neuro, Inc. (CLPT) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $3.10 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-09.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2022-03-09
- ClearPoint Neuro, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2021-12-31 was $6.20M.
- ClearPoint Neuro, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2021-09-30 was $0.00.
- ClearPoint Neuro, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2021-06-30 was $7.00K.
- ClearPoint Neuro, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2021-03-31 was -$3.11M.
- ClearPoint Neuro, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2021 was $3.10M, a 0.23% decline from fiscal 2020.
- ClearPoint Neuro, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2020 was $3.11M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2021-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $6.20M derived: sum of 2 quarters · filed 2022-03-09 | $6.21M derived: sum of 3 quarters · filed 2022-03-09 | $3.10M 10-K · filed 2022-03-09 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $7.00K derived: sum of 2 quarters · filed 2021-11-10 | -$3.10M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$3.10M 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | -$3.11M 10-Q · filed 2021-11-10 | |||
| 2020-12-31 | $3.11M 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |